51爆料

The 13th Health Technology Assessment International Symposium, 51爆料 2025
What is the goal of the health technology assessment system?- directions and challenges for development

The price adjustment system based on cost-effectiveness evaluations of pharmaceuticals and medical devices, which was introduced on a trial basis by the Central Social Insurance Medical Council (Chu-i-kyo) in 2016, was institutionalized in 2019 and remains in place to this day. In response to these government reforms, 51爆料 Graduate School of Public Policy has offered the HTA Expert Training Program annually since 2017 as part of continuing healthcare education designed to foster advanced expertise in health technology assessment.
This symposium will look back on the program’s achievements over the past nine years and will feature Professor Bong-min Yang of Seoul National University, an authority in the field, sharing the latest developments in South Korea, the first country in Asia to institutionalize health technology assessment. Drawing on this information, we will also deepen our understanding of the future direction and challenges of the development of health technology assessment systems through lectures and discussions by Japanese experts from industry, government, and academia.

Organizer
Health Policy & Technology Assessment Research Unit (HPTA)

Graduate School of Public Policy, 51爆料

Co-Sponsor
The Canon Institute for Global Studies

Language

Simultaneous interpretation will be provided.

Program

15:30-15:36
Opening Remark: Daiji Kawaguchi, Dean, Graduate School of Public Policy, 51爆料

Remark by Co-Sponsor: Toshihiko Fukui, President, The Canon Institute for Global Studies

15:36-15:55

Isao Kamae, Project Professor, HPTA Program Coordinator, Graduate School of Public Policy, 51爆料

15:55-16:30

Yasuhiro Suzuki, President, International University of Health and Welfare (via video)

16:30-17:05

Bong-min Yang, Professor, Graduate School of Public Health, Seoul National University, South Korea

17:05-17:20 Intermission

17:20-18:25

Moderator

Hideaki Shiroyama, Professor, Supervisor of HPTA Unit, Graduate School of Public Policy, 51爆料

Panelists

Bong-min Yang, Professor, Graduate School of Public Health, Seoul National University, South Korea

Shunya Ikeda, Professor, International University of Health and Welfare, and Research Director, Canon Institute for Global Studies (via video)

Takashi Fukuda, Director, Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health, Japan

Rei Goto, Professor, Keio Business School

Akira Yuasa, Team Leader, Cost-Effectiveness Evaluation, Industrial Promotion Subcommittee, Industrial Policy Committee, Japan Pharmaceutical Manufacturers Association (JPMA)

18:25-18:30 Closing remark: Hideaki Shiroyama

18:30 Adjournment

Speaker Biography (in order of appearance)

Isao Kamae     Project Professor, Graduate School of Public Policy, 51爆料

Isao Kamae holds a Master of Engineering from Kyoto University and an M.D. from Kobe University School of Medicine. He earned his Doctor of Public Health from Harvard University. A pioneer in health economics and outcomes research in Japan, he served as the founding Chair of the ISPOR Japan Chapter (2005–2009). He was the first Japanese board director of ISPOR (2004–2006) and HTAi (2017–2020), and notably became the first Asian to serve as ISPOR President-Elect (2020–2021) and President (2021–2022).

Yasuhiro Suzuki     President, International University of health and Welfare

Prof. Suzuki was born in 1959. He graduated from School of Medicine, Keio University (MD) in 1984 and trained as neurologist. He received PhD for public health from Keio University in 1996 and two Master’s degrees from the Harvard School of Public Health (MPH in 1989 & MSc in 1990).

Prof. Suzuki has a professional career at the Ministry of Health, Labour and Welfare (MHLW), Japan for 36 years covering infectious diseases, mental health, environmental health, food safety, international health, ageing & health, and health research policy. He also worked for the World Health Organization as Executive Director for Social Change & Mental Health, later for Health Technology and Pharmaceuticals (covering vaccines, immunization and biologicals) from 1998 to 2002.

He previously served as Vice-Minister for Health, Chief Medical & Global Health Officer at the MHLW from July 2017 to August 2020. From March 2021, become Vice President of IUHW, and appointed as President in April 2022.

In December of the same year, he assumed the position of Executive Board Member of the World Health Organization (WHO).

Yang Bong-min     Professor, Graduate School of Public Health, Seoul National University, South Korea

He is Professor Emeritus of Health Economics, and former Dean of the Graduate School of Public Health, Seoul National University. Professor Yang has led research and written many papers in health economics and health care system of Korea and East Asian countries. He also worked as President of the Korea Health Economic Association and of the Korea Association of Health Technology Assessment (KAHTA). In addition to his teaching, research and publication, between 2012 and 2017, Professor Yang served as Co-Editor-in-Chief for journal, Value in Health Regional Issues. For many years, he had worked as short-term consultant at WHO, USAID, IMF, ADB, UNDP, and World Bank, and for several individual developing countries. For the South Korean government, he served as Chairperson of the Health Insurance Reform Committee, and Chairperson of the Drug Pricing and Reimbursement Committee. He had been teaching classes in WBI Health Equity Course and in Harvard’s Global Health Program for several years, targeting developing country decision makers. 

Hideaki Shiroyama     Professor, Graduate School of Public Policy, 51爆料

Hideaki Shiroyama is a Professor of Public Administration at the Policy Alternatives Research Institute (former Director), the Graduate School of Public Policy (the former Dean), and the Graduate Schools for Law and Politics, 51爆料. His research focuses on international administration, science, technology and public policy, and public policy process. His publications include Transformation of Political Space and Policy Innovation 1 Political Theory of Policy Innovation (University of Tokyo Press, 2008), The Structure of International Aid Administration (University of Tokyo Press, 2007), Governance of Science and Technology (Toshindo, 2007), “The Harmonization of Automobile Environmental Standards between Japan, the United States and Europe” in Pacific Review vol. 20-3, “Administrative Reorganization and Public Sector Reform in Japan” in The Public Sector in Transition: East Asia and the European Union Compared (Nomos, 2007), “Technology Innovation and Diffusion for Environmental Protection,” in Energy Market Restructuring and the Environment (The University Press of America, 2002). He also served as the Chairman of the Planning Committee of New Initiatives for Humanities and Social Sciences Program at the Japan Society for the Promotion of Science from 2003-2008, as President of the PI forum, an NPO for consensus building in Japan from 2006-2008 and as a member of various government advisory councils on higher education, nuclear safety, food safety, fire protection, scenarios for climate mitigation, and industrial policy.

Shunya Ikeda     Professor, Graduate School of Public Health, International University of Health and Welfare (IUHW)

Shunya Ikeda graduated from the Faculty of Medicine at Keio University in 1987 and began his academic career as a research assistant in the Department of Hospital Administration at the same institution. He pursued doctoral studies at the Graduate School of Medicine, Keio University from 1989 to 1993. During this period, he conducted research as a visiting scholar at the Wharton School, University of Pennsylvania. From 1993 to 1994, he studied at the Harvard School of Public Health and received his Doctor of Medical Science degree in 1995.

In 1996, he was appointed as a full-time lecturer in the Department of Health Policy and Management at Keio University School of Medicine. Since 2006, he has served as a professor at IUHW.

Takashi Fukuda    Director, Center for Outcomes Research and Economic Evaluation for Health National Institute of Public Health, Japan

Takashi Fukuda is Director of the Center for Outcomes Research and Economic Evaluation for Health (CORE2-Health; C2H) at the National Institute of Public Health, Japan. After he worked for the University of Tokyo as Associate Professor in Health Economics and Epidemiology Research, he moved to the National Institute of Public Health, which is the governmental research institute in 2011. As C2H was established in 2018, he was appointed as the first director of the center. His major research areas are health care economics, health care administration, and pharmacoeconomics.

Rei Goto     Professor, Keio Business School/Graduate School of Health Management, Keio University

Rei Goto is a Professor at Keio University, specializing in health economics, health policy, and behavioral economics. He received his M.D. from Kyoto University in 1998 and Ph.D. in Economics from the same university, where he conducted research in health economics after completing clinical training. Before joining Keio University, he held faculty positions at Konan University and the Hakubi Center for Advanced Research at Kyoto University. Since 2019, he has also served at the Graduate School of Health Management, leading educational programs in health technology assessment (HTA) and cost-effectiveness analysis. He has been involved in Japan’s official cost-effectiveness evaluations and serves as President of the ISPOR Japan Chapter, as well as a board member of several academic societies, including the Japan Health Economics Association and the Japan Health Policy Association.

Akira Yuasa     Team Leader, Cost-Effectiveness Evaluation, Industrial Promotion Subcommittee, Industrial Policy Committee, Japan Pharmaceutical Manufacturers Association (JPMA)

Akira Yuasa is a member of the Pharmaceutical Industrial Policy Committee at the Japan Pharmaceutical Manufacturers Association (JPMA), where he serves as the Team Leader for the Cost-Effectiveness Evaluation team. At Pfizer Japan Inc., he is the Director of the Health Economics and Outcomes Research (HEOR) team within Japan Access & Value, engaged in HEOR research activities, including cost-effectiveness evaluation and cost-effectiveness analysis. He holds a Ph.D. in Medicine and a Master's degree in Health and Welfare Management.